Long-Acting Antiretrovirals: Where Are We now?

Amesika N. Nyaku, Sean G. Kelly, Babafemi O. Taiwo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


Purpose of Review: Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals. Recent Findings: Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Summary: Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.

Original languageEnglish (US)
Pages (from-to)63-71
Number of pages9
JournalCurrent HIV/AIDS Reports
Issue number2
StatePublished - Apr 1 2017


  • HIV prevention
  • HIV treatment
  • Long-acting antiretrovirals
  • Pre-exposure prophylaxis

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'Long-Acting Antiretrovirals: Where Are We now?'. Together they form a unique fingerprint.

Cite this